Overview

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gefitinib
Methotrexate